Literature DB >> 32043568

CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses.

Eugene Y Chiang1, Patricia E de Almeida1, Denise E de Almeida Nagata1, Kristin Harden Bowles1, Xiangnan Du1, Avantika S Chitre1, Karl L Banta1, Youngsu Kwon2, Brent McKenzie2, Stephanie Mittman3, Rafael Cubas3, Keith R Anderson4, Søren Warming4, Jane L Grogan1.   

Abstract

CD96 is a member of the poliovirus receptor (PVR, CD155)-nectin family that includes T cell Ig and ITIM domain (TIGIT) and CD226. While CD96, TIGIT, and CD226 have important roles in regulating NK cell activity, and TIGIT and CD226 have also been shown to regulate T cell responses, it is unclear whether CD96 has inhibitory or stimulatory function in CD8+ T cells. Here, we demonstrate that CD96 has co-stimulatory function on CD8+ T cells. Crosslinking of CD96 on human or mouse CD8+ T cells induced activation, effector cytokine production, and proliferation. CD96 was found to transduce its activating signal through the MEK-ERK pathway. CD96-mediated signaling led to increased frequencies of NUR77- and T-bet-expressing CD8+ T cells and enhanced cytotoxic effector activity, indicating that CD96 can modulate effector T cell differentiation. Antibody blockade of CD96 or genetic ablation of CD96 expression on CD8+ T cells impaired expression of transcription factors and proinflammatory cytokines associated with CD8+ T cell activation in in vivo models. Taken together, CD96 has a co-stimulatory role in CD8+ T cell activation and effector function.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CD8+ T cells; CD96; cellular activation; co-stimulation; signaling

Mesh:

Substances:

Year:  2020        PMID: 32043568     DOI: 10.1002/eji.201948405

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  23 in total

Review 1.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

2.  COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.

Authors:  Kyle Hansen; Sandeep Kumar; Kathryn Logronio; Sarah Whelan; Samir Qurashi; Hsin-Yuan Cheng; Andrew Drake; Margaret Tang; Patrick Wall; David Bernados; Ling Leung; Eran Ophir; Zoya Alteber; Gady Cojocaru; Moran Galperin; Masha Frenkel; Mark White; John Hunter; Spencer C Liang; Maya F Kotturi
Journal:  Cancer Immunol Immunother       Date:  2021-04-26       Impact factor: 6.968

3.  Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.

Authors:  Marion Thibaudin; Emeric Limagne; Léa Hampe; Elise Ballot; Caroline Truntzer; Francois Ghiringhelli
Journal:  Cancer Immunol Immunother       Date:  2022-03-16       Impact factor: 6.630

4.  Classification of human chronic inflammatory skin disease based on single-cell immune profiling.

Authors:  Yale Liu; Hao Wang; Mark Taylor; Christopher Cook; Alejandra Martínez-Berdeja; Jeffrey P North; Paymann Harirchian; Ashley A Hailer; Zijun Zhao; Ruby Ghadially; Roberto R Ricardo-Gonzalez; Roy C Grekin; Theodora M Mauro; Esther Kim; Jaehyuk Choi; Elizabeth Purdom; Raymond J Cho; Jeffrey B Cheng
Journal:  Sci Immunol       Date:  2022-04-15

5.  Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.

Authors:  Karl L Banta; Xiaozheng Xu; Avantika S Chitre; Amelia Au-Yeung; Chikara Takahashi; William E O'Gorman; Thomas D Wu; Stephanie Mittman; Rafael Cubas; Laetitia Comps-Agrar; Amit Fulzele; Eric J Bennett; Jane L Grogan; Enfu Hui; Eugene Y Chiang; Ira Mellman
Journal:  Immunity       Date:  2022-03-08       Impact factor: 43.474

Review 6.  TIGIT in cancer immunotherapy.

Authors:  Joe-Marc Chauvin; Hassane M Zarour
Journal:  J Immunother Cancer       Date:  2020-09       Impact factor: 13.751

7.  Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.

Authors:  Hyung-Seung Jin; Yoon Park
Journal:  BMB Rep       Date:  2021-01       Impact factor: 4.778

8.  CD96 Correlates With Immune Infiltration and Impacts Patient Prognosis: A Pan-Cancer Analysis.

Authors:  Wenrui Ye; Cong Luo; Fangkun Liu; Zhixiong Liu; Fenghua Chen
Journal:  Front Oncol       Date:  2021-02-19       Impact factor: 6.244

Review 9.  Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.

Authors:  Baokang Wu; Chongli Zhong; Qi Lang; Zhiyun Liang; Yizhou Zhang; Xin Zhao; Yang Yu; Heming Zhang; Feng Xu; Yu Tian
Journal:  J Exp Clin Cancer Res       Date:  2021-08-25

10.  Loss of CD96 Expression as a Marker of HIV-Specific CD8+ T-Cell Differentiation and Dysfunction.

Authors:  Rémi Bunet; Manon Nayrac; Hardik Ramani; Mohamed Sylla; Madeleine Durand; Carl Chartrand-Lefebvre; Jean-Pierre Routy; Alan L Landay; Jean-Francois Gauchat; Nicolas Chomont; Petronela Ancuta; Daniel E Kaufmann; Nicole Bernard; Cécile L Tremblay; Mohamed El-Far
Journal:  Front Immunol       Date:  2021-05-27       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.